Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models
Akari Therapeutics reported positive preclinical data at ASCO 2026 showing that its lead ADC, AKTX-101, exhibits synergistic cytotoxic activity when combined with the KRAS inhibitor adagrasib in pancreatic cancer models. The synergy was observed in KRAS G12D and G12C mutant cell lines, driven by the novel RNA spliceosome-modulating payload PH1, which targets pre-mRNA transcripts for degradation. This mechanism contrasts with conventional TROP2 ADCs using Topoisomerase I inhibitors, which showed antagonism with adagrasib in the same studies, highlighting a potential competitive differentiation for AKTX-101.
Key figures
- Drug Name
- AKTX-101
- Trial phase
- Preclinical
- Target timeline
- mid-2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.